12.1 Rheumatoid Arthritis: Autoimmune Pathophysiology, Manifestations & DMARD / Biologic Therapies

Rheumatoid Arthritis: Autoimmune Pathophysiology, Manifestations & DMARD / Biologic Therapies

Core Clinical Principle: Rheumatoid Arthritis (RA) is a chronic, systemic autoimmune disease characterized by persistent, symmetric, inflammatory synovitis that causes progressive cartilage degradation, juxta-articular bone erosion, and systemic extra-articular manifestations. Early, aggressive treatment with Disease-Modifying Antirheumatic Drugs (DMARDs) is imperative to arrest inflammatory pannus proliferation, preserve joint biomechanics, and prevent irreversible skeletal deformity and functional disability.

Unlike osteoarthritis, which is primarily a biomechanical disorder of articular cartilage degradation, RA is driven by an aberrant adaptive immune response against synovial neoepitopes. Understanding the immunopathology, physical diagnostic hallmarks, perioperative cervical spine vulnerabilities, and complex pharmacotherapeutic profiles is vital for the certified orthopaedic nurse.

---

1. Autoimmune Pathophysiology & Pannus Dynamics

The immunopathogenesis of RA involves a loss of self-tolerance in genetically susceptible individuals (frequently associated with HLA-DRB1 shared epitope alleles), triggered by environmental stimuli such as cigarette smoking, periodontal mucosal inflammation (Porphyromonas gingivalis), or microbiome dysbiosis.

                     IMMUNOPATHOGENIC CASCADE OF RHEUMATOID ARTHRITIS
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 1. Citrullination & Loss of Tolerance                                       │
  │    (PAD enzymes convert arginine to citrulline; neoantigen presentation)   │
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         ▼
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 2. T-Cell & B-Cell Activation in Synovium                                   │
  │    (CD4+ Th1/Th17 cells secrete IFN-γ, IL-17; B cells produce RF & anti-CCP)│
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         ▼
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 3. Synovial Hyperplasia, Neovascularization & Macrophage Recruitment        │
  │    (Massive release of Pro-inflammatory Cytokines: TNF-α, IL-1, IL-6)       │
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         ▼
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 4. Invasive Pannus Formation & Chondro-Osseous Destruction                  │
  │    (MMPs destroy type II collagen; RANKL activates osteoclastic erosion)    │
  └─────────────────────────────────────────────────────────────────────────────┘

The Invasive Pannus

Under continuous cytokine stimulation (principally Tumor Necrosis Factor-alpha [TNF-α], Interleukin-1 [IL-1], and Interleukin-6 [IL-6]), the normal delicate synovial lining (1–2 cell layers thick) undergoes massive hyperplastic proliferation, expanding into a hypertrophic, villous, highly vascularized granulation tissue termed pannus:

• Fibroblast-like Synoviocytes (FLS): Acquire an aggressive, tumor-like invasive phenotype and secrete high concentrations of Matrix Metalloproteinases (MMPs) (MMP-1, MMP-3, MMP-13) and aggrecanases that digest the extracellular proteoglycan and type II collagen matrix of articular hyaline cartilage.
• Osteoclastogenesis via RANKL: Synovial T-cells and fibroblasts upregulate Receptor Activator of Nuclear Factor-κB Ligand (RANKL), which binds to RANK receptors on osteoclast precursors, triggering massive mature osteoclast activation and driving characteristic marginal, periarticular bone erosions at the junction where synovial reflection meets bare bone.

---

2. Clinical Manifestations & Articular Distribution

RA typically presents as an insidious, progressive, symmetric polyarthritis affecting small and medium synovial joints. Systemic constitutional symptoms often precede or accompany joint involvement, including low-grade pyrexia, chronic fatigue, malaise, diffuse myalgias, anorexia, and involuntary weight loss.

Morning Stiffness & The Gel Phenomenon

• Prolonged Morning Stiffness: Lasts greater than 1 hour (frequently 2 to 3 hours or throughout the morning) and is a hallmark clinical indicator of active synovial inflammation. The stiffness resolves gradually with gentle physical activity and warm showers.
• The Gel Phenomenon: Inactivity leads to the accumulation of inflammatory exudate within the joint capsule; resting or prolonged sitting causes stiffening of the joints, which requires movement to disperse.

Joint Distribution Pattern

---

3. Classic Hand, Wrist & Foot Deformities

Chronic inflammatory synovitis stretches and degrades periarticular joint capsules, collateral ligaments, and extensor/flexor tendon sheaths, resulting in predictable structural collapse and biomechanical deformities:

                      CLASSIC RHEUMATOID HAND DEFORMITIES
  ┌─────────────────────────┬─────────────────────────┬─────────────────────────┐
  │ Ulnar Drift (Deviation) │ Swan-Neck Deformity     │ Boutonnière Deformity   │
  ├─────────────────────────┼─────────────────────────┼─────────────────────────┤
  │ • Extensor tendons slip │ • PIP joint             │ • Rupture of central    │
  │   ulnarly into the      │   HYPEREXTENSION        │   extensor tendon slip  │
  │   intermetacarpal valleys│ • DIP joint             │ • Lateral bands slip    │
  │ • Proximal phalanges    │   FLEXION               │   volarly               │
  │   deviate toward ulna   │ • Intrinsic tightness   │ • PIP FLEXION with      │
  │   at MCP joints         │   stretching volar plate│   DIP HYPEREXTENSION    │
  └─────────────────────────┴─────────────────────────┴─────────────────────────┘

Detailed Structural Deformities

1. Ulnar Drift / Deviation: Chronic MCP synovitis distends the joint capsule; normal biomechanical pinch forces cause the extensor digitorum communis tendons to slip off the apex of the metacarpal heads into the ulnar gutters, pulling the proximal phalanges into marked ulnar deviation.
2. Swan-Neck Deformity: Caused by contracture of the intrinsic hand muscles and attenuation/stretching of the PIP volar plate, leading to hyperextension of the Proximal Interphalangeal (PIP) joint accompanied by compensatory flexion of the Distal Interphalangeal (DIP) joint.
3. Boutonnière Deformity: Chronic PIP synovitis causes attenuation or rupture of the central slip of the extensor digitorum tendon over the dorsal PIP. The lateral bands subluxate volarly below the PIP axis of motion, acting as flexors: results in flexion of the PIP joint and reciprocal hyperextension of the DIP joint ('buttonhole' herniation of PIP through lateral bands).
4. Hitchhiker Thumb (Z-Deformity): Severe hyperextension of the interphalangeal (IP) joint with fixed flexion of the metacarpophalangeal (MCP) joint.
5. Volar Subluxation of the Wrist & Piano-Key Sign: Destruction of the radioulnar ligaments allows dorsal subluxation of the distal ulna; pressing downward on the distal ulna produces ballottement with spring-back recoil (piano-key sign).
6. Rheumatoid Foot Deformities: Hallux valgus, subluxation of the MTP heads with painful plantar callosities ('walking on marbles'), and claw toe/cock-up toe deformities.
7. Popliteal (Baker's) Cyst: Synovial effusion under pressure herniates into the gastrocnemio-semimembranosus bursa behind the knee. Rupture of a Baker's cyst releases inflammatory fluid into the deep calf tissues, closely mimicking an acute Deep Vein Thrombosis (pseudothrombophlebitis; mandates duplex ultrasound evaluation).

---

4. Extra-Articular Manifestations & Systemic Complications

As a systemic autoimmune disease, RA causes extensive extra-articular organ pathology mediated by circulating immune complexes and vascular endothelial inflammation:

• Subcutaneous Rheumatoid Nodules: Occur in 20%–30% of seropositive patients. Firm, non-tender, movable or fixed subcutaneous granulomatous masses featuring a central zone of fibrinoid necrosis surrounded by palisading histiocytes/macrophages. Located predominantly over extensor pressure surfaces (olecranon process, Achilles tendon, dorsal finger joints).
• Ophthalmic Manifestations: Keratoconjunctivitis sicca (secondary Sjögren syndrome), episcleritis, scleritis (deep boring ocular pain; risk of scleromalacia perforans and globe perforation).
• Pulmonary Involvement: Interstitial Lung Disease (ILD), rheumatoid pleural effusions (characterized by exudative fluid with extremely low glucose <30 mg/dL), and intrapulmonary rheumatoid nodules (Caplan syndrome in coal miners).
• Cardiovascular Pathology: Accelerated atherosclerosis (leading cause of mortality in RA), pericarditis, myocarditis, and coronary arteritis.
• Felty Syndrome: A severe, rare manifestation triad consisting of: 1) Long-standing seropositive RA, 2) Splenomegaly, and 3) Severe Neutropenia (Absolute Neutrophil Count [ANC] <2,000/μL), predisposing patients to recurrent life-threatening bacterial infections and non-healing leg ulcers.
• Rheumatoid Vasculitis: Necrotizing vasculitis of small-to-medium vessels causing cutaneous purpura, digital gangrene, peripheral neuropathy (mononeuritis multiplex), and deep cutaneous ulcers.

---

5. Diagnostic Evaluation & Laboratory Serologies

                  DIAGNOSTIC SEROLOGY & INFLAMMATORY MARKER MATRIX
  ┌─────────────────────┬─────────────────────┬─────────────────────┬──────────────────────────┐
  │ Diagnostic Test     │ Sensitivity         │ Specificity         │ Clinical & Prognostic    │
  │                     │                     │                     │ Significance             │
  ├─────────────────────┼─────────────────────┼─────────────────────┼──────────────────────────┤
  │ Anti-CCP / ACPA     │ 70% – 80%           │ 95% – 98%           │ High specificity; early  │
  │ (Anti-Citrullinated)│                     │ (HIGH)              │ predictor of aggressive, │
  │                     │                     │                     │ erosive joint disease.   │
  ├─────────────────────┼─────────────────────┼─────────────────────┼──────────────────────────┤
  │ Rheumatoid Factor   │ 70% – 80%           │ 70% – 80%           │ Autoantibody against IgG │
  │ (RF - IgM isotype)  │                     │ (MODERATE)          │ Fc; present in SLE, SSc, │
  │                     │                     │                     │ hepatitis C, infections. │
  ├─────────────────────┼─────────────────────┼─────────────────────┼──────────────────────────┤
  │ ESR & CRP           │ Variable            │ Non-specific        │ Mirrors systemic burden; │
  │ (Phase Reactants)   │                     │                     │ CRP correlates with daily│
  │                     │                     │                     │ active inflammation.     │
  ├─────────────────────┼─────────────────────┼─────────────────────┼──────────────────────────┤
  │ Synovial Fluid      │ High for            │ High for Group II   │ WBC 2,000–50,000/μL;     │
  │ Analysis            │ inflammation        │ category            │ >50% PMNs; low viscosity;│
  │                     │                     │                     │ excludes crystal/septic. │
  └─────────────────────┴─────────────────────┴─────────────────────┴──────────────────────────┘

Radiographic Hallmarks (ACR / EULAR Criteria)

• Early Disease: Soft-tissue swelling, periarticular osteopenia (demineralization adjacent to inflamed synovium due to local osteoclast activation).
• Established Disease: Symmetric uniform joint space narrowing, marginal bone erosions (loss of cortical line at bone-cartilage junction), subchondral cyst formation, and progressive subluxation/ankylosis.

---

6. Preoperative Cervical Spine Evaluation: Atlantoaxial Subluxation (AAS)

One of the most critical safety responsibilities of the orthopaedic nurse caring for an RA patient undergoing surgery is ensuring proper cervical spine clearance.

               ATLANTOAXIAL SUBLUXATION (AAS) MECHANISM & PROTOCOL
  ┌────────────────────────────────────────────────────────────────────────┐
  │ 1. RA Synovitis at Synovial-Lined Atlanto-Odontoid Articulation        │
  │    (Inflammatory pannus erodes the Transverse Ligament of the Atlas)   │
  └───────────────────────────────────┬────────────────────────────────────┘
                                      ▼
  ┌────────────────────────────────────────────────────────────────────────┐
  │ 2. C1 (Atlas) Shifts Anteriorly Relative to C2 (Axis / Odontoid)       │
  │    (Loss of ligamentous restraint allows anterior translation on C1)   │
  └───────────────────────────────────┬────────────────────────────────────┘
                                      ▼
  ┌────────────────────────────────────────────────────────────────────────┐
  │ 3. Narrowing of Spinal Canal / Cord Compression During Neck Flexion     │
  │    (Extending or flexing neck during intubation can crush spinal cord) │
  └───────────────────────────────────┬────────────────────────────────────┘
                                      ▼
  ┌────────────────────────────────────────────────────────────────────────┐
  │ 4. MANDATORY PREOPERATIVE PROTOCOL:                                    │
  │    • Cervical Spine Flexion-Extension Radiographs                      │
  │    • Anterior Atlantodental Interval (ADI) > 3 mm (abnormal), > 8 mm   │
  │      indicates severe instability and cord compression risk.           │
  │    • Fiberoptic / Video-Laryngoscopy Intubation in Neutral Alignment   │
  └────────────────────────────────────────────────────────────────────────┘

Critical Clinical Warning

• The Danger: Routine direct endotracheal intubation involves forceful neck hyperextension and anterior traction. In an unstable cervical spine with transverse ligament attenuation, this movement can translate the odontoid process (dens) directly into the cervicomedullary junction, resulting in quadriparesis/tetraplegia, diaphragmatic respiratory paralysis, or sudden cardiac arrest.
• Nursing Action: Screen every RA patient for symptoms of cervical myelopathy (occipital headaches, neck pain radiating to the vertex, paresthesias in hands/feet, Lhermitte sign [electric shock down spine upon neck flexion], hyperreflexia, Clonus, positive Babinski sign). Verify that cervical spine flexion and extension radiographs have been completed and cleared prior to transfer to the operating room.

7. Pharmacotherapeutic Management: DMARDs & Biologics

Modern management follows the 'Treat-to-Target' (T2T) paradigm, initiating disease-modifying agents immediately upon clinical diagnosis to achieve clinical remission or low disease activity (measured via DAS28 or CDAI scores).

                      PHARMACOTHERAPEUTIC HIERARCHY IN RA
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Phase 1: Conventional Synthetic DMARDs (csDMARDs)                           │
  │ • Methotrexate (First-Line Anchor Drug) | Leflunomide | Sulfasalazine       │
  │ • Hydroxychloroquine (Mild disease / Combination therapy)                   │
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         ▼ (Inadequate response at 3 months)
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Phase 2: Biologic DMARDs (bDMARDs) or Targeted Synthetic DMARDs (tsDMARDs)  │
  │ • TNF-α Inhibitors: Adalimumab, Etanercept, Infliximab, Golimumab           │
  │ • Non-TNF Biologics: Tocilizumab (IL-6), Abatacept (T-cell), Rituximab (CD20)│
  │ • JAK Inhibitors: Tofacitinib, Upadacitinib, Baricitinib                    │
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         ▼
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Bridging / Adjunctive Therapy: NSAIDs & Short-Course Low-Dose Corticosteroids│
  │ • Rapid symptomatic relief while awaiting DMARD onset (6–12 weeks)          │
  │ • Taper corticosteroids rapidly to prevent osteoporosis and joint necrosis  │
  └─────────────────────────────────────────────────────────────────────────────┘

Comprehensive Drug Profiles & Nursing Surveillance

---

8. Perioperative Biologic & DMARD Management Protocols

Patients with RA frequently undergo orthopaedic reconstruction (total knee, hip, or shoulder arthroplasty, fusion, and tenosynovectomy). Managing immunomodulatory drugs perioperatively requires balancing the risk of postoperative infection with the risk of an acute rheumatoid disease flare.

                  PERIOPERATIVE DMARD & BIOLOGIC PROTOCOL (ACR / AAHKS)
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 1. Conventional Synthetic DMARDs (Methotrexate, Hydroxychloroquine)         │
  │    • CONTINUE WITHOUT INTERRUPTION throughout the perioperative window      │
  │      (High-quality trials prove continuing MTX does NOT increase infection  │
  │       and significantly reduces severe postoperative RA flare rates).       │
  └─────────────────────────────────────────────────────────────────────────────┘
                                         │
  ┌──────────────────────────────────────┴──────────────────────────────────────┐
  │ 2. Biologic DMARDs & Targeted Synthetics (TNF Inhibitors, JAK Inhibitors)    │
  │    • HOLD PRIOR TO SURGERY: Schedule surgery at the END of the dosing cycle│
  │      (e.g., for adalimumab [every 2 weeks], withhold for 1 full cycle,      │
  │       operating in week 3).                                                 │
  │    • RESUME POSTOPERATIVELY: Re-initiate only after ALL criteria are met:   │
  │      a) Surgical wound is completely healed (epithelialized)                │
  │      b) All sutures or staples have been removed (typically 10–14 days)     │
  │      c) Zero evidence of local surgical site or systemic infection          │
  │      d) Any postoperative empiric or therapeutic antibiotics completed      │
  └─────────────────────────────────────────────────────────────────────────────┘

---

9. Comprehensive Orthopaedic Nursing Interventions & Patient Education

• Joint Protection Principles:
  • Instruct patients to distribute loads across larger, stronger joints (e.g., carrying a shoulder tote bag or carrying objects with forearms and palms rather than pinching with fingers).
  • Utilize ergonomic assistive devices: wide-grip kitchen utensils, spring-loaded scissors, lever door handles, and key turners.
  • Avoid maintaining joints in a single flexed position for prolonged periods; avoid tight pinching or twisting motions (e.g., opening tight jars, which exerts ulnar deviation torque on MCPs).
• Balancing Rest and Exercise:
  • During Acute Flares: Emphasize joint rest, gentle passive/active-assisted range of motion to preserve planes of movement without provoking pain, and application of cold packs to suppress acute synovial hyperemia.
  • During Remission / Low Activity: Implement regular low-impact aerobic conditioning (aquatic therapy, stationary bicycling) and isometric/isotonic strengthening to reinforce periarticular muscular support without loading damaged joint surfaces.
• Splinting & Orthoses: Use resting volar splints at night to support wrists in neutral (10°–15° extension) and prevent flexion contractures and ulnar drift progression.